Reconstitution of hTERT restores tumorigenicity in melanoma-derived c-Myc low-expressing clones

被引:27
作者
Biroccio, A
Amodei, S
Benassi, B
Scarsella, M
Cianciulli, A
Mottolese, M
Del Bufalo, D
Leonetti, C
Zupi, G [1 ]
机构
[1] Regina Elena Inst Canc Res, Expt Chemotherapy Lab, Rome, Italy
[2] Regina Elena Inst Canc Res, Clin & Pathol Labs, Rome, Italy
关键词
c-Myc; telomerase; tumorigenicity; apoptosis; melanoma;
D O I
10.1038/sj.onc.1205415
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
c-Myc is involved in the control of telomerase activity through its ability to induce the expression of the catalytic subunit of the enzyme, the human telomerase reverse transcriptase (hTERT). Our aim was to study whether telomerase plays a critical role in c-Myc-dependent tumorigenicity of melanoma cells. By using M14-derived clones, expressing low levels of c-Myc, we demonstrated that the down-regulation of c-Myc reduced cell proliferation rate, cloning efficiency and tumorigenicity and increased the apoptotic rate. Decreased tumorigenic potential correlated with reduced hTERT gene expression, telomerase activity and telomere shortening. Introduction of wild-type hTERT into these cells increased their proliferation rate and partially re-established their tumorigenic potential, at early passages, even though the apoptotic rate of the population remained unaltered. After several in vitro passages, hTERT-mediated cell proliferation made the tumorigenic potential of the c-Myc low-expressing clones comparable to that of the M14 parental line. Over-expression of the mutant biologically inactive hTERT did not drive cells to proliferate. In conclusion, our results demonstrate that the reconstitution of high levels of telomerase activity reverses the low tumorigenicity due to low c-Myc expression.
引用
收藏
页码:3011 / 3019
页数:9
相关论文
共 48 条
  • [1] Telomerase and cancer: Revisiting the telomere hypothesis
    Autexier, C
    Greider, CW
    [J]. TRENDS IN BIOCHEMICAL SCIENCES, 1996, 21 (10) : 387 - 391
  • [2] THE ORNITHINE DECARBOXYLASE GENE IS A TRANSCRIPTIONAL TARGET OF C-MYC
    BELLOFERNANDEZ, C
    PACKHAM, G
    CLEVELAND, JL
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (16) : 7804 - 7808
  • [3] C-myc down-regulation increases susceptibility to cisplatin through reactive oxygen species-mediated apoptosis in M14 human melanoma cells
    Biroccio, A
    Benassi, B
    Amodei, S
    Gabellini, C
    Del Bufalo, D
    Zupi, G
    [J]. MOLECULAR PHARMACOLOGY, 2001, 60 (01) : 174 - 182
  • [4] Extension of life-span by introduction of telomerase into normal human cells
    Bodnar, AG
    Ouellette, M
    Frolkis, M
    Holt, SE
    Chiu, CP
    Morin, GB
    Harley, CB
    Shay, JW
    Lichtsteiner, S
    Wright, WE
    [J]. SCIENCE, 1998, 279 (5349) : 349 - 352
  • [5] CHADENEAU C, 1995, ONCOGENE, V11, P893
  • [6] p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis
    Chin, L
    Artandi, SE
    Shen, Q
    Tam, A
    Lee, SL
    Gottlieb, GJ
    Greider, CW
    DePinho, RA
    [J]. CELL, 1999, 97 (04) : 527 - 538
  • [7] Citro G, 1998, CANCER RES, V58, P283
  • [8] THE MYC ONCOGENE - ITS ROLE IN TRANSFORMATION AND DIFFERENTIATION
    COLE, MD
    [J]. ANNUAL REVIEW OF GENETICS, 1986, 20 : 361 - 384
  • [9] Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization
    Counter, CM
    Hahn, WC
    Wei, WY
    Caddle, SD
    Beijersbergen, RL
    Lansdorp, PM
    Sedivy, JM
    Weinberg, RA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (25) : 14723 - 14728
  • [10] c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations
    D'Cruz, CM
    Gunther, EJ
    Boxer, RB
    Hartman, JL
    Sintasath, L
    Moody, SE
    Cox, JD
    Ha, SI
    Belka, GK
    Golant, A
    Cardiff, RD
    Chodosh, LA
    [J]. NATURE MEDICINE, 2001, 7 (02) : 235 - 239